# Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma

> **NCT02408016** · PHASE1,PHASE2 · TERMINATED · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 11 (actual)

## Conditions studied

- Advanced Pleural Malignant Mesothelioma
- HLA-A*0201 Positive Cells Present
- Recurrent Non-Small Cell Lung Carcinoma
- Recurrent Pleural Malignant Mesothelioma
- Stage III Non-Small Cell Lung Cancer AJCC v7
- Stage III Pleural Malignant Mesothelioma AJCC v7
- Stage IIIA Non-Small Cell Lung Cancer AJCC v7
- Stage IIIB Non-Small Cell Lung Cancer AJCC v7
- Stage IV Non-Small Cell Lung Cancer AJCC v7
- Stage IV Pleural Malignant Mesothelioma AJCC v7
- WT1 Positive

## Interventions

- **BIOLOGICAL:** Aldesleukin
- **BIOLOGICAL:** Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes
- **DRUG:** Cyclophosphamide
- **OTHER:** Laboratory Biomarker Analysis
- **PROCEDURE:** Therapeutic Conventional Surgery

## Key facts

- **NCT ID:** NCT02408016
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-05-22
- **Primary completion:** 2020-06-30
- **Final completion:** 2020-06-30
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Terminated due to loss of funding
- **Last updated:** 2021-09-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02408016

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02408016, "Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02408016. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*